Table 4.

Prevalence of Mycoplasma genitalium and resistance profiles

	Total (N=726)	95% CI
N with sample tested	719
M. genitalium positive	41 (5.7)	4.0 to 7.4§
23S
A2058G*	3 (7.3)	1.5 to 19.9
A2058T*	2 (4.9)	0.6 to 16.5
A2059G*	3 (7.3)	1.5 to 19.9
No sequence*	15 (36.6)	22.1 to 53.1
WT*	18 (43.9)	28.5 to 60.3
Mutation related to azithromycin resistance†	8/26 (30.8)	14.3 to 51.8
GyrA
95MET(ATG)→ILE(ATC)*	1 (2.4)	0.06 to 12.9
Inconclusive*	1 (2.4)	0.06 to 12.9
No sequence*	12 (29.3)	16.1 to 45.5
WT*	25 (60.9)	49.4 to 79.9
GyrA mutation †	1/26 (3.8)	0.09 to 18.4
ParC
83SER(AGT)→ILE(ATT)*	1 (2.4)	0.06 to 12.9
83SER(AGT)→ASN(AAT)*	0	0 to 8.6
Inconclusive*	9 (22.0)	10.6 to 37.6
No sequence*	14 (34.2)	20.1 to 50.6
WT‡	17 (41.5)	26.3 to 57.9
ParC mutation†	1/18 (5.6)	0.14 to 27.3
M. genitalium negative	678 (94.3)	92.6 to 96.0§
M. genitalium positive	1 (5.9)	0.15 to 28.7
M. genitalium negative	16 (94.1)	71.3 to 99.9

Data presented as N (%).

*Per cent of positive for M. genitalium.

†Denominator is positive samples with conclusive sequencing results.

‡Wild type.

§Exact 95% CIs except for which are based on the normal approximation.